• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Aegerion Pharmaceuticals

edit

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.

Milestones

edit

• 
  Aegerion Pharmaceuticals added Marc Beer as CEO & Director.
  Posted 9/15/10 at 6:52pm
• 
  Aegerion Pharmaceuticals received $1.5M in Venture Round funding. (10/11/10)
  Posted 10/11/10 at 5:32pm via wsj.com
• 
  Aegerion Pharmaceuticals — received positive data from a Phase 3 trial of its potential treatment for a rare genetic type of extremely high cholesterol (6/1/11)
  Posted 6/2/11 at 6:06am via masshightech.com
• 
  Aegerion Pharmaceuticals — granted orphan drug designation from the U.S. Food and Drug Administration for its treatment of familial chylomicronemia (FC), a rare genetic disorder (3/16/11)
  Posted 3/17/11 at 5:06am via masshightech.com
• 
  Aegerion Pharmaceuticals — has named Martha Carter as chief regulatory officer (2/7/11)
  Posted 2/8/11 at 3:54am via masshightech.com

Videos

Screenshots

edit

Sources

1. IPO Hopeful Aegerion Pharmaceuticals Returns To Investors For $1.5M (online.wsj.com) [edit]
Aegerion names regulatory vet Carter to CRO post (masshightech.com) [edit]
Aegerion gains orphan drug status for lipid disorder drug (masshightech.com) [edit]
Aegerion returns positive data for cholesterol treatment (masshightech.com) [edit]